期刊文献+

尾加压素Ⅱ在妊娠期糖尿病孕妇血清及胎盘中的表达及意义 被引量:1

Expressions and significance of urotensin Ⅱ in serum and placenta of pregnant women with gestational diabetes mellitus
原文传递
导出
摘要 目的探讨正常孕妇和妊娠期糖尿病(GDM)孕妇血清和胎盘中尾加压素Ⅱ(UⅡ)的表达及其临床意义。方法选取2012年6月-2013年12月在该院正规产检并住院分娩的孕妇80例,其中正常孕妇40例(对照组),GDM孕妇40例(观察组)。采用酶联免疫吸附试验(ELISA)法检测两组孕妇外周血血清中的UⅡ水平;采用RT-PCR观察胎盘中UⅡmRNA的表达。结果两组孕妇血清中UⅡ水平值比较,差异有统计学意义(t=2.32,P〈0.05);两组孕妇胎盘组织中UⅡmRNA表达水平比较,差异有统计学意义(t=1.67,P〈0.05);两组血清UⅡ水平与胎盘组织UⅡmRNA表达水平均呈正相关(r=0.73,P〈0.05;r=0.72,P〈0.05)。结论 UⅡ在GDM孕妇血清及胎盘中的高表达提示其参与了GDM的发生与发展。 Objective To explore the expressions and clinical significance of urotensin Ⅱ( UⅡ) in serum and placenta of normal pregnant women and pregnant women with gestational diabetes mellitus( GDM). Methods Eighty hospitalized pregnant women receiving prenatal examination in the hospital from June 2012 to December 2013 were selected and divided into control group( 40 normal pregnant women) and observation group( 40 GDM pregnant women). ELISA was used to detect serum UⅡ levels in peripheral blood of women in the two groups; RT- PCR was used to observe the expression of UⅡ mRNA in placenta. Results There was statistically significant difference in serum UⅡ level between the two groups( t = 2. 32,P 〈0. 05); there was statistically significant difference in expression level of UⅡ mRNA in placenta between the two groups( t = 1. 67,P 〈0. 05); in the two groups,there were positive correlations between serum UⅡ levels and expression levels of UⅡ mRNA in placenta( r = 0. 73,P 〈0. 05; r = 0. 72,P 〈0. 05). Conclusion High expressions of UⅡ in serum and placenta of GDM women are related to occurrence and development of GDM.
出处 《中国妇幼保健》 CAS 2015年第27期4706-4708,共3页 Maternal and Child Health Care of China
基金 武汉市卫计委卫生科研项目〔WX15C32〕
关键词 尾加压素Ⅱ 妊娠期糖尿病 胎盘组织 Urotensin Ⅱ Gestational diabetes mellitus Placental tissue
  • 相关文献

参考文献16

  • 1Kim C.Gestational diabetes mellitus in korean women:similarities and differences from other racial/ethnic groups[J].Diabetes Metab J,2014,38(1):1-12.
  • 2You Z,Al Kindi H,Abdul-Karim A,et al.Blocking the urotensinⅡreceptor pathway ameliorates the metabolic syndrome and improves cardiac function in obese mice[J].FASEB J,2014,28(3):1210-1220.
  • 3Watson AM,Olukman M,Koulis C,et al.UrotensinⅡreceptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis:studies in humans and in a mouse model of diabetes[J].Diabetologia,2013,56(5):1155-1165.
  • 4Barrette PO,Schwertani AG.A closer look at the role of urotensinⅡin the metabolic syndrome[J].Front Endocrinol,2012,28(3):165.
  • 5乐杰主编.妇产科学[M].第7版,北京:人民卫生出版社.2013:348.
  • 6Vaudry H,Do Rego JC,Le Mevel JC,et al.UrotensinⅡ,from fish to human[J].Ann N Y Acad Sci,2010,134(1200):53-66.
  • 7Merlino F,Di Maro S,Munaim Yousif A,et al.Urotensin-Ⅱligands:an overview from peptide to nonpeptide structures[J].J Amino Acids,2013,2013:979016.
  • 8Okumus S,Igci YZ,Taskin T,et al.Association between Thr21Met and Ser89Asn Polymorphisms of the urotensin-Ⅱ(UTS2)gene,diabetes mellitus,and diabetic retinopathy[J].Curr Eye Res,2012,37(10):921-929.
  • 9Lau SM.Comment on:Rowan et al.Metformin in Gestational diabetes:the offspring follow-up(Mi G TOFU):body composition at 2 years of age[J].Diabetes Care,2012,35(3):e29.
  • 10Gould PS,Gu M,Liao J,et al.Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia[J].Hypertension,2010,56(1):172-178.

二级参考文献67

  • 1陶少平,陈学峰,孙艳,杭宇,周蓓.黄芪注射液对糖尿病肾病患者血转化生长因子-β_1及Ⅳ型胶原水平的影响及其意义[J].中国中西医结合肾病杂志,2006,7(3):156-157. 被引量:42
  • 2陈瑶,李倩,汪翼,李燕,王玉林.肥胖儿童血浆血管假性血友病因子与动脉粥样硬化指数的相关性分析[J].中国实用儿科杂志,2006,21(11):865-866. 被引量:9
  • 3Pearson D, Shively JE, Clark BR, Geschwind, II, Barkley M, Nishioka RS, Bern HA. Urotensin II: a somatostatin-like peptide in the caudal neurosecretory system of fishes. Proc Natl Acad Sci U S A 1980; 77 (8): 5021-5024.
  • 4Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM, Louden CS, Foley JJ, Sauermelch CF, Coatney RW, Ao Z, Disa J, Holmes SD, Stadel JM, Martin JD, Liu WS, Glover GI, Wilson S, McNulty DE, Ellis CE, Elshourbagy NA, Shabon U, Trill JJ, Hay DW, Ohlstein EH, Bergsma DJ, Douglas SA. Human urotensin-I1 is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999; 401 (6750): 282-286.
  • 5Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002; 359 (9322): 1990-1997.
  • 6Dschietzig T, Bartsch C, Pregla R, Zurbrugg HR, Armbruster FP, Richter C, Laule M, Romeyke E, Neubert C, Voelter W, Baumann G, Stangl K. Plasma levels and cardiovascular gene expression of urotensin-II in human heart failure. Regul Pept 2002; 110 (1): 33-38.
  • 7Douglas SA, Ashton DJ, Sauermelch CF, Coatney RW, Ohlstein DH, Ruffolo MR, Ohlstein EH, Aiyar NV, Willette RN. Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate. J Cardiovasc Pharmacol 2000; 36 (5 Suppl 1): S163-S166.
  • 8Coulouarn Y, Fernex C, Jegou S, Henderson CE, Vaudry H, Lihrmann I. Specific expression of the urotensin II gene in sacral motoneurons of developing rat spinal cord. Mech Dev 2001; 101 (1-2): 187-190.
  • 9Filipeanu CM, Brailoiu E, Le Dun S, Dun NJ. Urotensin-II regulates intracellular calcium in dissociated rat spinal cord neurons. J Neurochem 2002; 83 (4): 879-884.
  • 10Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P, de Garavilla L, Li PL, Zou AP. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003; 285 (4): F792- F798.

共引文献14

同被引文献6

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部